In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp

Abstract Fusarium spp is an opportunistic fungal pathogen responsible for causing invasive hyalohyphomycosis in immunocompromised patients. Due to its susceptibility pattern with a remarkable resistance to antifungal agents the treatment failures and mortality rates are high. To overcome this situat...

Full description

Saved in:

Bibliographic Details
Published in:	Diagnostic microbiology and infectious disease Vol. 71; no. 2; pp. 126 - 130
Main Authors:	Venturini, Tarcieli P, Rossato, Luana, Spader, Tatiana B, Tronco-Alves, Giordano R, Azevedo, Maria Izabel, Weiler, Caroline B, Santurio, Janio M, Alves, Sydney Hartz
Format:	Journal Article
Language:	English
Published:	New York, NY Elsevier Inc 01-10-2011 Elsevier
Subjects:	Amphotericin B - pharmacology Antifungal agents Antifungal Agents - pharmacology Associations Biological and medical sciences Drug Synergism Fundamental and applied biological sciences. Psychology Fungi - drug effects Fusarium Fusarium - drug effects Fusarium spp Ibuprofen - pharmacology Infectious Disease Infectious diseases Internal Medicine Itraconazole - pharmacology Medical sciences Microbial Sensitivity Tests Microbiology Miscellaneous Mycology Pyrimidines - pharmacology Susceptibility Synergism Triazoles - pharmacology Voriconazole Associations Susceptibility Synergism Antifungal agents Fusarium spp Azole derivatives In vitro Fungi Infection Antiprotozoal agent Antibiotic Antifungal agent Sensitivity Amphotericin B Polyenic compound Voriconazole Triazole derivatives Fusarium Parasiticide Fungi Imperfecti
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Fusarium spp is an opportunistic fungal pathogen responsible for causing invasive hyalohyphomycosis in immunocompromised patients. Due to its susceptibility pattern with a remarkable resistance to antifungal agents the treatment failures and mortality rates are high. To overcome this situation, combination therapy may be considered which must be subjected to in vitro tests. In vitro activities of amphotericin B, itraconazole, and voriconazole associated with azithromycin, ciprofloxacin, fluvastatin, ibuprofen, metronidazole, and also the combination of amphotericin B plus rifampin against 23 strains of Fusarium spp. through the checkerboard technique based on M38-A2 [Clinical and Laboratory Standards Institute (2008). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. (CLSI document M38-A2) (ISBN 1-56238-668-9). Wayne, PA: CLSI] were evaluated. The best synergistic interactions with amphotericin B were with ibuprofen (43.5%) (FICI [fractional inhibitory concentration index] range = 0.25–2). Combinations with voriconazole showed synergism, mainly with ciprofloxacin (30.4%) (FICI range = 0.25–3) and metronidazole (30.4%) (FICI range = 0.1–4); however, all the combinations with itraconazole were indifferent. In general, antagonistic interactions were not registered. Our results showed that in vitro synergisms obtained by some combinations studied deserve attention since they were better than those showed by the antimycotic.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0732-8893 1879-0070
DOI:	10.1016/j.diagmicrobio.2011.05.007